EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Time to Think Antifungal Resistance

Thomas S McCormick, Mahmoud Ghannoum

Pathogens and Immunity · 05.03.2024 · 8 (2) · 158-176

DOI: 10.20411/pai.v8i2.656 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens and Immunity, online erschienen am 05.03.2024. Verfasst von Thomas S McCormick und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Center for Medical Mycology, Case Western Reserve University, Cleveland, Ohio. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increased antifungal resistance is exacerbating the burden of invasive fungal infections, as well as potentially contributing to the increase in resistant dermatomycoses. In this commentary, we focus on antifungal drug resistance, in contrast to antibacterial resistance. We provide a brief historical perspective on the emergence of antifungal resistance and propose measures for combating this growing health concern. The increase in the incidence of invasive and cutaneous fungal infections parallels advancements in medical interventions, such as immunosuppressive drugs, to manage cancer and reduce organ rejection following transplant. A disturbing relatively new trend in antifungal resistance is the observation of several fungal species that now exhibit multidrug resistance (eg, Candida auris, Trichophyton indotineae). Increasing awareness of these multidrug-resistant species is paramount. Therefore, increased education regarding potential fungus-associated infections is needed to address awareness in the general healthcare setting, which may result in a more realistic picture of the prevalence of antifungal-resistant infections. In addition to education, increased use of diagnostic tests (eg, micro and macro conventional assays or molecular testing) should be routine for healthcare providers facing an unknown fungal infection. Two critical barriers that affect the low rates for Antifungal Susceptibility Testing (AST) are low (or a lack of) sufficient insurance reimbursement rates and the low number of qualified laboratories with the capacity to perform AST. The ultimate aim is to improve the quality of patient care through fungal identification, diagnosis, and, where appropriate, susceptibility testing. Here we propose an all-encompassing call to action to address this emerging challenge.

Schlagwörter

Stichwörter der Autor:innen

Antifungal ResistanceDermatophytosisRecommendationTerbinafine ResistanceTrichophytan indotineae

Autor:innen und Institutionen

  • Department of Dermatology, Center for Medical Mycology, Case Western Reserve University, Cleveland, Ohio.
  • University Hospitals Cleveland Medical Center, Cleveland, Ohio.

Zitieren

APA

McCormick, T. S., & Ghannoum, M. (2024). Time to Think Antifungal Resistance. Pathogens and Immunity, 8(2), 158-176. https://doi.org/10.20411/pai.v8i2.656

Vancouver

McCormick TS, Ghannoum M. Time to Think Antifungal Resistance. Pathogens and Immunity. 2024;8(2):158-176. doi:10.20411/pai.v8i2.656

BibTeX
@article{McCormick2024,
  author = {McCormick, Thomas S and Ghannoum, Mahmoud},
  title = {Time to Think Antifungal Resistance},
  journal = {Pathogens and Immunity},
  year = {2024},
  volume = {8},
  number = {2},
  pages = {158--176},
  doi = {10.20411/pai.v8i2.656}
}
Kostenlos starten →